Genetic and epigenetic changes in lung carcinoma and their clinical implications
暂无分享,去创建一个
Wei Zhang | Jian-Hua Fu | Jing Wen | Wei Zhang | Ming Guo | Jing Wen | Jianhua Fu | Ming Guo | J. Fu
[1] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[2] M. Spitz,et al. Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer , 2008, British Journal of Cancer.
[3] O. Witt,et al. HDAC family: What are the cancer relevant targets? , 2009, Cancer letters.
[4] Hong Peng,et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. , 2010, Lung cancer.
[5] D. Sidransky,et al. Cigarette smoking is strongly associated with mutation of the K‐ras gene in patients with primary adenocarcinoma of the lung , 2001, Cancer.
[6] A. Hezel,et al. LKB1; linking cell structure and tumor suppression , 2008, Oncogene.
[7] G. Bepler,et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Jänne,et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. , 2006, Cancer cell.
[9] Yuki Togashi,et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.
[10] Hisao Asamura,et al. Promoter Methylation of DAL-1/4.1B Predicts Poor Prognosis in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[11] H. Benjamin,et al. Accurate Classification of Non–Small Cell Lung Carcinoma Using a Novel MicroRNA-Based Approach , 2010, Clinical Cancer Research.
[12] J. Luketich,et al. Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. , 2006, Neoplasia.
[13] J. L. Bos,et al. ras oncogenes in human cancer: a review. , 1989, Cancer research.
[14] H. Koong,et al. Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-small Cell Lung Cancer (NSCLC) , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[15] A. Puisieux,et al. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. , 1991, Cancer research.
[16] Y. Tomizawa,et al. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers. , 2007, International journal of oncology.
[17] Takayuki Kosaka,et al. Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] J. Minna,et al. Exclusive mutation in epidermal growth factor receptor gene, HER‐2, and KRAS, and synchronous methylation of nonsmall cell lung cancer , 2006, Cancer.
[19] A. Yoshizawa,et al. Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene , 2010, Annals of Surgical Oncology.
[20] Ichiro Yoshino,et al. Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. , 2008, International journal of oncology.
[21] M. O’Connor-McCourt,et al. Expression of P185erbB-2, P160erbB-3, P180erbB-4, and heregulin alpha in human normal bronchial epithelial and lung cancer cell lines. , 1999, Anticancer research.
[22] M. Esteller. Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.
[23] H. Geddert,et al. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer , 2006, Cancer.
[24] Bernat Gel,et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. , 2009, Carcinogenesis.
[25] William Pao,et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.
[26] Julie A Hong,et al. Apoptosis Induced by Depsipeptide FK228 Coincides with Inhibition of Survival Signaling in Lung Cancer Cells , 2007, Cancer journal.
[27] W. Travis,et al. The new World Health Organization classification of lung tumours , 2001, European Respiratory Journal.
[28] I. Yoshino,et al. Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers. , 2009, International journal of oncology.
[29] W. Park,et al. Somatic mutations of the ERBB4 kinase domain in human cancers , 2006, International journal of cancer.
[30] J. Lafitte,et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. , 2001, The European respiratory journal.
[31] Shanna H. Swan,et al. A Specific Spectrum of p53 Mutations in Lung Cancer from Smokers: Review of Mutations Compiled in the IARC p53 Database , 1998, Environmental Health Perspectives.
[32] Y. Ouchi,et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras–MAPK signaling in human cancer cells , 2006, Oncogene.
[33] S. Rodenhuis,et al. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. , 1991, Journal of the National Cancer Institute.
[34] Sung-Liang Yu,et al. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. , 2010, Cancer research.
[35] E. Shimizu,et al. Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells. , 2005, Oncology reports.
[36] Yanqin Sun,et al. miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. , 2010, Biochemical and biophysical research communications.
[37] D. R. Jones. Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer , 2008 .
[38] T. Brunner,et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. , 2009, Cancer research.
[39] Jin-Yuan Shih,et al. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. , 2005, The New England journal of medicine.
[40] L. Kopelovich,et al. The epigenome as a target for cancer chemoprevention. , 2003, Journal of the National Cancer Institute.
[41] J. Park,et al. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. , 2007, Cancer genetics and cytogenetics.
[42] Gideon Rechavi,et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] 土井 誠志. The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells , 2009 .
[44] M. Meyerson,et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[45] J S Lee,et al. Clonal genetic alterations in the lungs of current and former smokers. , 1997, Journal of the National Cancer Institute.
[46] C. Harris,et al. p53 and K-ras mutations in lung cancers from former and never-smoking women. , 2001, Cancer research.
[47] J. Herman,et al. Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. , 2001, Cancer research.
[48] S. Rodenhuis,et al. K‐ras oncogene activation in lung adenocarcinomas from former smokers evidence that K‐ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung , 1993 .
[49] Yang Shi,et al. Ineffectiveness of Histone Deacetylase Inhibitors to Induce Apoptosis Involves the Transcriptional Activation of NF-κB through the Akt Pathway* , 2003, Journal of Biological Chemistry.
[50] David Sidransky,et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. , 2002, Cancer research.
[51] E. Mark,et al. Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer. , 2001, Cancer research.
[52] S. Toyooka,et al. Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers , 2005, International journal of cancer.
[53] S. Horvath,et al. Global levels of histone modifications predict prognosis in different cancers. , 2009, The American journal of pathology.
[54] D. Neil Hayes,et al. LKB1 modulates lung cancer differentiation and metastasis , 2007, Nature.
[55] J. Coon,et al. PTEN, RASSF1 and DAPK site‐specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients , 2010, International journal of cancer.
[56] M. Spitz,et al. 3p22.1 and 10q22.3 Deletions Detected by Fluorescence In Situ Hybridization (FISH): A Potential New Tool for Early Detection of Non-small Cell Lung Cancer (NSCLC) , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[57] H. Sasaki,et al. ErbB4 expression and mutation in Japanese patients with lung cancer. , 2007, Clinical lung cancer.
[58] H. Hsu,et al. Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. , 2007, Lung cancer.
[59] A. Gazdar. Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy , 2010, Cancer and Metastasis Reviews.
[60] Lesley Seymour,et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] Chih-Yi Chen,et al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. , 2010, The Journal of clinical investigation.
[62] J. Califano,et al. Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer. , 2005, Cancer research.
[63] P. Hainaut,et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. , 2007, Cancer research.
[64] Xi Chen,et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] A. Marchetti,et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. , 1997, Cancer research.
[66] L. Mariani,et al. FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer. , 2008, Current cancer drug targets.
[67] Junxia Chen,et al. Let‐7a elevates p21WAF1 levels by targeting of NIRF and suppresses the growth of A549 lung cancer cells , 2009, FEBS letters.
[68] J. Minna,et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.
[69] Molecular Damage in the Bronchial Epithelium of Current and Former Smokers , 1997 .
[70] H. Sasaki,et al. EGFR and erbB2 mutation status in Japanese lung cancer patients , 2006, International journal of cancer.
[71] J. Luketich,et al. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[72] Jung Young Lee,et al. ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas , 2006, International journal of cancer.
[73] J. Carretero,et al. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene , 2004, Oncogene.
[74] P. Hainaut,et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. , 2005, Cancer research.
[75] F. Khuri,et al. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. , 1999, Cancer research.
[76] Carlos L Arteaga,et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. , 2006, Cancer cell.
[77] S. Digumarthy,et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] Clay B Marsh,et al. MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. , 2009, Biochemical and biophysical research communications.
[79] A. Gazdar,et al. Aberrant methylation of SPARC in human lung cancers , 2005, British Journal of Cancer.
[80] William C Hahn,et al. Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants , 2005, PLoS medicine.
[81] R. Rosell,et al. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] H. Bartsch,et al. The role of individual susceptibility in cancer burden related to environmental exposure. , 1996, Environmental health perspectives.
[83] Roy S Herbst,et al. KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.
[84] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[85] B. Ylstra,et al. Genomic Profiles Associated with Early Micrometastasis in Lung Cancer: Relevance of 4q Deletion , 2009, Clinical Cancer Research.
[86] Yucai Wang,et al. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. , 2007, Lung cancer.
[87] Jingde Zhu,et al. RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China , 2009, Journal of Cancer Research and Clinical Oncology.
[88] M. Hung,et al. Overexpression of the c‐erbB‐2/neu–encoded p185 protein in primary lung cancer , 1992, Molecular carcinogenesis.
[89] M. Higuchi,et al. Prognostic impact of p53 protein overexpression in patients with node-negative lung adenocarcinoma. , 2006, Cancer letters.
[90] R. Stephens,et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.
[91] Anthony J Alberg,et al. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.
[92] A. Iafrate,et al. Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.
[93] S. Kobayashi,et al. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. , 2009, Clinical lung cancer.
[94] Andrew D. Yates,et al. Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.
[95] M. Ohira,et al. Aberrant methylation of FBN2 in human non-small cell lung cancer. , 2005, Lung cancer.
[96] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[97] W. Park,et al. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas , 2005, Virchows Archiv.
[98] J. Jen,et al. Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. , 2000, Cancer research.
[99] Ya‐Wen Cheng,et al. Potential Increase in the Prognostic Value of p53 Mutation by Pro72 Allele in Stage I Non-Small-Cell Lung Cancer , 2009, Annals of Surgical Oncology.
[100] Derek Y. Chiang,et al. Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.
[101] H. Varmus,et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. , 2006, Genes & development.
[102] Bo Liu,et al. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. , 2009, Lung cancer.
[103] Sreenath V. Sharma,et al. ErbBs in lung cancer. , 2009, Experimental cell research.
[104] Michael Thomas,et al. Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. , 2005, Cancer research.
[105] Y. Yatabe,et al. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients , 2004, International journal of cancer.
[106] Sung-Liang Yu,et al. MicroRNA signature predicts survival and relapse in lung cancer. , 2008, Cancer cell.
[107] Y. Shim,et al. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] Yoshitaka Fujii,et al. Histone deacetylase 1 mRNA expression in lung cancer. , 2004, Lung cancer.
[109] Sébastien Couraud,et al. Lung cancer in never smokers--a review. , 2012, European journal of cancer.
[110] Yi Zhang,et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. , 2006, Cancer research.
[111] Yuki Togashi,et al. EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[112] Shi-Yong Sun,et al. LKB1 mutation in large cell carcinoma of the lung. , 2006, Lung cancer.
[113] Yuh-Shan Jou,et al. Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer , 2005, International journal of cancer.
[114] D. Weiner,et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. , 1990, Cancer research.
[115] Y. Yamashita,et al. Risk for K-ras gene mutations in smoking-induced lung cancer is associated with cytochrome P4501A1 and glutathione S-transferase micro1 polymorphisms. , 2004, Oncology reports.
[116] Vassilis Georgoulias,et al. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. , 2008, Clinical chemistry.
[117] Y. Katayama,et al. Effect of IFN-β on human glioma cell lines with temozolomide resistance , 2009 .
[118] Gen Tamura,et al. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. , 2007, Lung cancer.
[119] Tyson V. Sharp,et al. The chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development , 2008, Proceedings of the National Academy of Sciences.
[120] G. Pershagen,et al. p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. , 2000, Cancer research.
[121] S. Zöchbauer-Müller,et al. Lung cancer: From single-gene methylation to methylome profiling , 2010, Cancer and Metastasis Reviews.
[122] D. Amadori,et al. p16INK4A and CDH13 hypermethylation in tumor and serum of non‐small cell lung cancer patients , 2006, Journal of cellular physiology.
[123] A. Hartmann,et al. Deletions at chromosome 2q and 12p are early and frequent molecular alterations in bronchial epithelium and NSCLC of long-term smokers. , 2005, International journal of oncology.
[124] H. Sugimura,et al. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. , 2008, Lung cancer.
[125] A. Iafrate,et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. , 2008, Cancer research.
[126] L. Seymour,et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] F. Caponigro,et al. Downstream intracellular effectors of epidermal growth factor receptor as targets for anticancer therapy , 2007, Expert opinion on therapeutic targets.
[128] Peter A. Jones,et al. Epigenetics in cancer. , 2010, Carcinogenesis.
[129] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[130] M. Meyerson,et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.
[131] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[132] J. Herman,et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. , 2006, Cancer research.
[133] Shu Zheng,et al. MicroRNA‐183 regulates Ezrin expression in lung cancer cells , 2008, FEBS letters.
[134] Yung-Hyun Choi. Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells. , 2005, International journal of oncology.
[135] G. Nuovo,et al. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. , 2008, Biochemical and biophysical research communications.
[136] Laura A. Sullivan,et al. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.
[137] E. Campo,et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. , 2009, The American journal of pathology.
[138] K. Schuebel,et al. Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. , 2009, Carcinogenesis.
[139] K. Aldape,et al. Alterations of 9p in squamous cell carcinoma and adenocarcinoma of the lung: association with smoking, TP53, and survival. , 2005, Cancer genetics and cytogenetics.
[140] Steven Piantadosi,et al. DNA methylation markers and early recurrence in stage I lung cancer. , 2008, The New England journal of medicine.
[141] Gesine Hansen,et al. Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma. , 2005, Lung cancer.
[142] S. Piantadosi,et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. , 2001, Cancer research.
[143] N. Hanna,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .
[144] J. Minna,et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers , 2007, Oncogene.
[145] M. Ladanyi,et al. Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma , 2008, Clinical Cancer Research.
[146] Y. Yatabe,et al. Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.
[147] H. J. Kim,et al. Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC. , 2005, European journal of cancer.
[148] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[149] D. Beer,et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. , 2009, Cancer research.
[150] D. Bigner,et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. , 1993, Cancer research.
[151] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[152] Y. Yarden,et al. ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti‐cancer therapy , 2006, International Journal of Cancer.
[153] Paolo Boffetta,et al. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. , 2009, Cancer research.
[154] E. Dmitrovsky,et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. , 2010, The Journal of clinical investigation.
[155] G. Giaccone,et al. Global histone modifications predict prognosis of resected non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[156] D. Christiani,et al. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. , 1998, Cancer research.
[157] M. Ridanpää,et al. K‐ras mutations in human adenocarcinoma of the lung: Association with smoking and occupational exposure to asbestos , 1993, International journal of cancer.
[158] L. Horvath,et al. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma , 2008, British Journal of Cancer.